Press Releases April 14, 2026 08:00 PM

BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026

BillionToOne to announce Q1 2026 financial results on May 6, 2026, with a follow-up conference call scheduled

By Priya Menon BLLN
BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026
BLLN

BillionToOne, a molecular diagnostics company traded on NASDAQ under the ticker BLLN, will release its financial results for the first quarter of 2026 on May 6, 2026, followed by a conference call to discuss the results. The company specializes in advanced DNA molecular counting technology aimed at creating accessible, powerful diagnostic tests.

Key Points

  • BillionToOne plans to report its Q1 2026 financial results on May 6, 2026 after market close.
  • A conference call to discuss these results is scheduled the same day to provide insights to investors and analysts.
  • The company is focused on molecular diagnostics, specifically its patented Quantitative Counting Templates technology which enables precise DNA molecule counting at the single-molecule level.

MENLO PARK, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, May 6, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested listeners will be available on the “Events” page of BillionToOne’s investor relations website at https://investors.billiontoone.com/.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com.

Investor Contact
[email protected]

Media Contact
[email protected]


Risks

  • Financial results may not meet market expectations, causing potential stock price volatility.
  • Dependence on successful commercialization of patented technology in a competitive molecular diagnostics sector.
  • Uncertainties related to regulatory approvals and adoption of new diagnostic tests that could impact revenue growth.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026